Nouryant (istradefylline)
- Region
- 🇪🇺 EU
- Active substance
- istradefylline
- Company
- Kyowa Kirin Holdings B.V.
- Status
- Refused
- Therapeutic area
- Parkinson Disease
- CHMP opinion
- Thu 22 Jul 2021
- Application
- EMEA/H/C/005308
- ATC
- N04
- Official record
- www.ema.europa.eu
Indication
Istradefylline is indicated in adults as an adjunctive treatment to levodopa based regimens in patients with Parkinson’s disease (PD) experiencing “OFF” time.
Regulatory milestones
No milestones recorded in the last year.
Follow Nouryant
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.